The CHMP adopted a positive opinion for an extension to the Avastin breast cancer label in Europe to include use in combination with Xeloda as a first-line treatment for metastatic breast cancer. The submission was based on results from the RIBBON 1 study which showed a significant increase in progression-free survival when Avastin was combined with capecitabine compared to capecitabine alone. Final approval from the European Commission is expected later this year, which would provide physicians and patients with more choice in selecting treatment options.
Treatment of Ovarian Cancer First Line Chemotherapy or Targeted Therapy for R...ijtsrd
Ovarian cancer is the seventh most common gynecological cancer worldwide, ovarian cancer is the eighth leading cause of cancer death in women. In recent years, the number of ovarian cancer cases has been increasing in Japan, more than 9,000 women are diagnosed with ovarian cancer each year. The 5 year survival rate is 58 , the lowest among gynecological cancers, 4,758 ovarian cancer deaths in 2012. That is, it is reported that about one in two ovarian cancer patients has died. Because it is difficult to cure recurrent ovarian cancer, treatment is used to prolong life and improve quality of life. Because PARP inhibitors are oral targeted drugs that specifically act on cancer cells, they are expected to reduce the risk of disease progression and death while maintaining a good safety profile. In this way, the development of oral preparations has made it possible to avoid the burden on patients such as pain caused by conventional injections and the time constraints required for infusion. In this review, we discuss new treatments for ovarian cancer. Takuma Hayashi | Kaoru Abiko | Ken Yamaguchi | Junzo Hamanishi | Masaki Mandan | Ikuo Konishi "Treatment of Ovarian Cancer: First-Line Chemotherapy or Targeted Therapy for Recurrent Cases" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-4 | Issue-3 , April 2020, URL: https://www.ijtsrd.com/papers/ijtsrd30470.pdf Paper Url :https://www.ijtsrd.com/medicine/other/30470/treatment-of-ovarian-cancer-firstline-chemotherapy-or-targeted-therapy-for-recurrent-cases/takuma-hayashi
Treatment of Ovarian Cancer First Line Chemotherapy or Targeted Therapy for R...ijtsrd
Ovarian cancer is the seventh most common gynecological cancer worldwide, ovarian cancer is the eighth leading cause of cancer death in women. In recent years, the number of ovarian cancer cases has been increasing in Japan, more than 9,000 women are diagnosed with ovarian cancer each year. The 5 year survival rate is 58 , the lowest among gynecological cancers, 4,758 ovarian cancer deaths in 2012. That is, it is reported that about one in two ovarian cancer patients has died. Because it is difficult to cure recurrent ovarian cancer, treatment is used to prolong life and improve quality of life. Because PARP inhibitors are oral targeted drugs that specifically act on cancer cells, they are expected to reduce the risk of disease progression and death while maintaining a good safety profile. In this way, the development of oral preparations has made it possible to avoid the burden on patients such as pain caused by conventional injections and the time constraints required for infusion. In this review, we discuss new treatments for ovarian cancer. Takuma Hayashi | Kaoru Abiko | Ken Yamaguchi | Junzo Hamanishi | Masaki Mandan | Ikuo Konishi "Treatment of Ovarian Cancer: First-Line Chemotherapy or Targeted Therapy for Recurrent Cases" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-4 | Issue-3 , April 2020, URL: https://www.ijtsrd.com/papers/ijtsrd30470.pdf Paper Url :https://www.ijtsrd.com/medicine/other/30470/treatment-of-ovarian-cancer-firstline-chemotherapy-or-targeted-therapy-for-recurrent-cases/takuma-hayashi
FDA Approves Genentech’s Avastin® (Bevacizumab) Plus Chemotherapy as a Treatm...Dr Matthew Boente MD
Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has approved Avastin® (bevacizumab) in combination with chemotherapy (carboplatin and paclitaxel), followed by Avastin as a single agent, for the treatment of women with advanced (stage III or IV) ovarian cancer following initial surgical resection.
This downloadable slidedeck, presented in a regional grand rounds series, focuses on increasing awareness about current and emerging treatment options for patients with newly diagnosed and recurrent ovarian cancer.
How to have quality of life in Advanced ovarian malignancyRajesh Gajbhiye
Presentation given by Dr Rakhi Gajbhiye, Mauli Hospital Nagpur at MGIMS sewagram for an International conference on Womens Health Fatal Disorders Survival with Quality in collaboration with FOGSI.
This was the function to commemorate 100 th birth centenary of Dr Sushila
FDA Approves Genentech’s Avastin® (Bevacizumab) Plus Chemotherapy as a Treatm...Dr Matthew Boente MD
Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has approved Avastin® (bevacizumab) in combination with chemotherapy (carboplatin and paclitaxel), followed by Avastin as a single agent, for the treatment of women with advanced (stage III or IV) ovarian cancer following initial surgical resection.
This downloadable slidedeck, presented in a regional grand rounds series, focuses on increasing awareness about current and emerging treatment options for patients with newly diagnosed and recurrent ovarian cancer.
How to have quality of life in Advanced ovarian malignancyRajesh Gajbhiye
Presentation given by Dr Rakhi Gajbhiye, Mauli Hospital Nagpur at MGIMS sewagram for an International conference on Womens Health Fatal Disorders Survival with Quality in collaboration with FOGSI.
This was the function to commemorate 100 th birth centenary of Dr Sushila
Protocol for the Treatment Prostate Cancer - Dr Serge JurasunasSheldon Stein
Dr. Serge Jurasunas shares his Prostate Cancer Protocol in this paper, explaining the nature and treatment of Prostate Cancer from a Naturopathic Oncology Perspective. Professor Jurasunas is located in Lisbon Portugal and has lectured worldwide throughout his 50 years as a clinician.
He explains what can be done about the #1 cause of death in males even before lung cancer and what can be done, from the new perspective of Naturopathic Oncology.He offers an example, explains diagnostic procedures with Molecular markers and addresses detox, supplements and treatment.
Further information may be found in his new book, Health and Disease Begin in the Colon" and in his Blog: Naturopathiconcology.blogspot.com .
ASCO 2014 Highlights: Breast Cancer, Prostate Cancer; AI diagnosingdianecleverley
American Society of Clinical Oncology, 2014.
ALTTO: all groups did well.
IOM reports: Out-of-pocket costs, termed financial toxicity, are a side effect of this disease.
Obese women with ER+ breast cancer are at a greater risk.
WATSON-like Artificial Intelligence computer program useful in as daignosis aid
Basavarajeeyam is a Sreshta Sangraha grantha (Compiled book ), written by Neelkanta kotturu Basavaraja Virachita. It contains 25 Prakaranas, First 24 Chapters related to Rogas& 25th to Rasadravyas.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of the physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar lead (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
6. Describe the flow of current around the heart during the cardiac cycle
7. Discuss the placement and polarity of the leads of electrocardiograph
8. Describe the normal electrocardiograms recorded from the limb leads and explain the physiological basis of the different records that are obtained
9. Define mean electrical vector (axis) of the heart and give the normal range
10. Define the mean QRS vector
11. Describe the axes of leads (hexagonal reference system)
12. Comprehend the vectorial analysis of the normal ECG
13. Determine the mean electrical axis of the ventricular QRS and appreciate the mean axis deviation
14. Explain the concepts of current of injury, J point, and their significance
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. Chapter 3, Cardiology Explained, https://www.ncbi.nlm.nih.gov/books/NBK2214/
7. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
ABDOMINAL TRAUMA in pediatrics part one.drhasanrajab
Abdominal trauma in pediatrics refers to injuries or damage to the abdominal organs in children. It can occur due to various causes such as falls, motor vehicle accidents, sports-related injuries, and physical abuse. Children are more vulnerable to abdominal trauma due to their unique anatomical and physiological characteristics. Signs and symptoms include abdominal pain, tenderness, distension, vomiting, and signs of shock. Diagnosis involves physical examination, imaging studies, and laboratory tests. Management depends on the severity and may involve conservative treatment or surgical intervention. Prevention is crucial in reducing the incidence of abdominal trauma in children.
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachAyurveda ForAll
Explore the benefits of combining Ayurveda with conventional Parkinson's treatments. Learn how a holistic approach can manage symptoms, enhance well-being, and balance body energies. Discover the steps to safely integrate Ayurvedic practices into your Parkinson’s care plan, including expert guidance on diet, herbal remedies, and lifestyle modifications.
Avastin with Xeloda as a first-line treatment for metastatic breast cancer
1. Media Release
Basel, 15 April 2011
Roche gains positive CHMP opinion for the combination of Avastin with Xeloda
as a first-line treatment for metastatic breast cancer in Europe
Approval would allow combination of Avastin with paclitaxel or Xeloda, offering more choice to
physicians and patients
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the Committee for Medicinal Products for
Human Use (CHMP) has adopted a positive opinion for an extension to the Avastin (bevacizumab) breast
cancer label in Europe. The application proposed the use of Avastin in combination with Xeloda
(capecitabine) for the first-line treatment of women with metastatic breast cancer in whom treatment with
other chemotherapy options including taxanes and anthracyclines is not considered appropriate. Avastin is
already approved in Europe in combination with paclitaxel chemotherapy in this setting.
The submission to expand the label was based on results from the phase III RIBBON 1 study which showed
a significant increase in the length of time women lived without their disease getting worse (progression-free
survival) when Avastin was combined with capecitabine compared to those who received capecitabine alone.
The current EU Avastin licence for metastatic breast cancer is for combination use with paclitaxel
chemotherapy. However taxane-based chemotherapy is not suitable for all patients. The RIBBON 1 study
showed that Avastin in combination with capecitabine could give these women an additional first-line
therapy choice. Final approval from the European Commission is expected later this year.
“We are pleased the CHMP has determined that Avastin in combination with capecitabine provides a
meaningful clinical benefit in metastatic breast cancer, affording physicians and patients more choice in
selecting an appropriate treatment option,” said Hal Barron M.D., Chief Medical Officer and Head, Global
Product Development. “Avastin is the only anti-angiogenic therapy approved to treat HER2-negative
metastatic breast cancer in Europe and the capecitabine data from the RIBBON 1 study, which was the basis
of this positive opinion, add to the clinical evidence supporting the use of Avastin as a treatment for this
disease”.
F. Hoffmann-La Roche Ltd 4070 Basel Group Communications Tel. +41 61 688 88 88
Switzerland Roche Group Media Relations Fax +41 61 688 27 75
www.roche.com
1/4
2. RIBBON 1 showed that Avastin in combination with capecitabine resulted in:
• A 45 percent increase in the likelihood of women being alive without disease progression compared to
those who received capecitabine alone (hazard ratio=0.69; p=0.0002).
• A median PFS of 8.6 months compared to 5.7 months in those women that received capecitabine alone.
• 35.4% of women experiencing a major shrinkage of their tumour compared to 23.6% of those receiving
capecitabine alone (p= 0.0097).
RIBBON 1 adds to the existing clinical evidence demonstrating the benefits of Avastin in metastatic breast
cancer. The pivotal E2100 (Avastin and paclitaxel) study forms the basis of the currently approved EU label
allowing combination of Avastin with paclitaxel to treat women with metastatic breast cancer.
About Avastin: Over 5 Years of Transforming Cancer Care
With the initial approval in the USA for advanced colorectal cancer in 2004, Avastin became the first anti-
angiogenic therapy made widely available for the treatment of patients with an advanced cancer.
Today, Avastin is continuing to transform cancer care through its proven survival benefit (overall survival
and/or progression free survival) across several types of cancer. Avastin is approved in the US and Europe
for the treatment of advanced stages of colorectal cancer, breast cancer, non-small cell lung cancer and
kidney cancer, and Avastin is also available in the US and over 31 other countries for the treatment of
patients with glioblastoma (a type of brain cancer). Avastin is the only anti-angiogenic therapy available for
the treatment of these numerous advanced cancer types, which collectively cause over 2.5 million deaths
each year.
Avastin has made anti-angiogenic therapy a fundamental pillar of cancer treatment today – over three
quarters of a million patients have been treated with Avastin so far. A comprehensive clinical programme
with more than 500 ongoing clinical trials is investigating the use of Avastin in over 50 tumor types
(including colorectal, breast, non-small cell lung, brain, gastric, ovarian and others) and different settings
(advanced or early stage disease).
About Avastin: Mode of Action
Avastin is an antibody that specifically binds and blocks the biological effects of VEGF (vascular endothelial
growth factor). VEGF is the key driver of tumor angiogenesis – a fundamental process required for a tumor
to grow and to spread (metastasise) to other parts of the body. Avastin’s precise mode of action allows it to
2/4
3. be combined effectively with a broad range of chemotherapies and other anti-cancer treatments. Avastin
helps to control tumor growth and extend survival with only a limited impact on the side effects of
chemotherapy.
About Xeloda (capecitabine)
Xeloda (capecitabine) is a highly effective targeted oral chemotherapy offering patients a survival advantage
when taken on its own or in combination with other anticancer drugs. Xeloda uniquely activates the cancer-
killing agent 5-FU (5-fluorouracil) directly inside the cancer cells. Xeloda tablets can be taken by patients in
their own home, reducing the number of hospital or clinic visits.
Licensed and marketed by Roche in more than 100 countries worldwide, Xeloda has over 11 years proven
clinical experience providing an effective and flexible treatment option to over 1.8 million people with
cancer. Xeloda is currently approved in:
Metastatic Breast Cancer
- Monotherapy in patients with tumours resistant to taxanes and anthracyclines – (US) 1998 and (EU)
2002
- In combination with docetaxel in patients whose disease has progressed following IV chemotherapy
with anthracyclines – (US) 2001 and (EU) 2002
- In patients with inoperable or recurrent breast cancer – (Japan) 2003
Metastatic Colorectal Cancer
- Monotherapy first-line (US , EU and ROW) – 2001
- In combination with any chemotherapy in all lines of treatment with or without Avastin (EU/ROW) –
2008
- In combination with oxaliplatin for the treatment of patients with advanced or refractory colorectal
cancer who are not candidates for curative surgery (Japan) – 2009
Adjuvant Colon Cancer
- Monotherapy (US & EU) – 2005
- Monotherapy (Japan) – 2007
- In combination with oxaliplatin as XELOX (EU) – 2010
Advanced Gastric Cancer
3/4
4. - First-line treatment (South Korea) – 2002
- In combination with platinum-based chemotherapy first-line (EU and ROW) – 2007
About Roche
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined
strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly
differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world
leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s
personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible
improvements in the health, quality of life and survival of patients. In 2010, Roche had over 80’000
employees worldwide and invested over 9 billion Swiss francs in R&D. The Group posted sales of 47.5
billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a
majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.
All trademarks used or mentioned in this release are protected by law.
Additional information
- Roche in Oncology: www.roche.com/media/media_backgrounder/media_oncology.htm
Roche Group Media Relations
Phone: +41 -61 688 8888 / e-mail: basel.mediaoffice@roche.com
- Alexander Klauser (Head)
- Silvia Dobry
- Daniel Grotzky
- Claudia Schmitt
- Annette Walz
4/4